Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019

Lutz, Halle; Popowski, Kristen D.; Dinh, Phuong‐Uyen; Cheng, Ke

doi:10.1002/anbr.202000063

Cited by 5 publications

(5 citation statements)

References 115 publications

(273 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the case of SARS-CoV-2, they induce rather low neutralizing responses, an observation compatible with the fact that most individuals infected with virus mount relatively low antibody responses despite sometimes rather high viral load. The same argument extends to attenuated viruses [16][17][18]. Adenoviruses-based vaccines targeting COVID-19 can easily be produced at large scale and can also be stored at conventional temperature (4 • C).…”

Section: Introductionmentioning

confidence: 91%

A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain

et al. 2021

View full text Add to dashboard Cite

COVID-19 has emerged, and has rapidly become a major health problem worldwide, causing millions of mortalities. Vaccination against COVID-19 is the most efficient way to stop the pandemic. The goal of vaccines is to induce neutralizing antibodies against SARS-CoV-2 virus. Here, we present a novel double mosaic virus-like particle (VLP) displaying two independent neutralizing epitopes, namely the receptor binding motif (RBM) located in S1 and the fusion peptide (AA 817–855) located in S2. CuMVTT virus-like particles were used as VLP scaffold and both domains were genetically fused in the middle of CuMVTT subunits, which co-assembled into double mosaic particles (CuMVTT-DF). A single fusion mosaic particle (CuMVTT-FP) containing the fusion peptide only was used for comparison. The vaccines were produced in E. coli, and electron microscopy and dynamic light scattering confirmed their integrity and homogeneity. In addition, the CuMVTT-DF vaccine was well recognized by ACE2 receptor, indicating that the RBM was in native conformation. Both CuMVTT-FP and CuMVTT-DF vaccines induced high levels of high avidity IgG antibodies as well as IgA recognizing spike and RBD in the case of CuMVTT-DF. Both vaccine candidates induced virus-neutralizing antibodies indicating that the fusion peptide can independently induce virus-neutralizing antibodies. In contrast, CuMVTT-DF containing both RBM and fusion peptide induced a higher level of neutralizing antibodies suggesting that the new double mosaic vaccine candidate CuMVTT-DF consisting of two antigens in one VLP maybe an attractive candidate for scale-up in a bacterial fermentation process for clinical development.

show abstract

Section: Introductionmentioning

confidence: 91%

A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Exosomes are particularly promising due to their cell membrane proteins and natural cargo of nucleic acids, proteins, and lipids, meaning exosomes display parent cell-specific targeting and functions (Popowski et al, 2020). These particles' biocompatible membranes are also able to avoid immune recognition and reduce toxic effects (Lutz et al, 2021). Furthermore, exosome surfaces can be engineered to display ligands for improved targeting and controlled release and their cargo can be altered to carry pharmaceutical drugs (Lutz et al, 2019).…”

Section: Cell-derived Biomaterials For Inflammationmentioning

confidence: 99%

Biomaterials for treating sepsis-induced thromboinflammation

Lutz,

Brown

2023

Front. Biomater. Sci.

Self Cite

View full text Add to dashboard Cite

Sepsis is a common and life-threatening disorder with an alarmingly high mortality rate. Unfortunately, this rate has not decreased significantly over the last decade and the number of septic cases is increasing each year. Despite sepsis affecting millions of people annually, there is still not an established standard of care. The development of a therapy that targets the thromboinflammation characteristic of sepsis is imperative. Until recently, research has focused on uncovering individual pathways to target. As more of the pathophysiology of sepsis has become understood and more biomarkers uncovered, the interplay between endothelial cells, platelets, and leukocytes has emerged as a critical event. Therefore, a multi-targeted approach is clearly required for designing an effective treatment for sepsis. The versatility of biomaterials offers a promising solution in that they can be designed to target and affect multiple pathways and systems and safely inhibit excessive inflammation while maintaining hemostasis. Already, studies have demonstrated the ability of biomaterials to target different processes and stages in sepsis-induced inflammation and coagulopathy. Moreover, some biomaterials offer inherent anti-inflammatory and hemostatic qualities. This review aims to discuss the most recent advancements in biomaterial development designed to address inflammation, coagulopathy, and thromboinflammation.

show abstract

“…Additionally, exosomes can be synthetically supplemented to enhance cellular targeting and therapeutic efficacy. 33 , 34 , 35 For example, anti-inflammatory peptides 36 can be linked onto the exosomal membrane, engineering an immune cell targeting nanomedicine. The combination of vesicle derivation and supplementation allows for a customizable nanoparticle delivery platform that can be utilized across many lung diseases.…”

Section: Introductionmentioning

confidence: 99%